Citadel Advisors
FTH

Citadel Advisors’s Faeth Therapeutics FTH Stock Holding History

Citadel Advisors’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
+12,296
New +$284K ﹤0.01% 11068
2025
Q1 		– Sell
-2,886
Closed -$28.3K – 15488
2024
Q4 		$28.3K Sell
2,886
-416
-13% -$4.17K ﹤0.01% 12925
2024
Q3 		$39.5K Buy
3,302
+2,534
+330% +$30.9K ﹤0.01% 12155
2024
Q2 		$9.53K Sell
768
-425
-36% -$8.84K ﹤0.01% 13135
2024
Q1 		$25.1K Sell
1,193
-97
-8% -$1.67K ﹤0.01% 12845
2023
Q4 		$17.9K Buy
+1,290
New +$17.6K ﹤0.01% 12721
2022
Q3 		– Sell
-2,969
Closed -$134K – 13540
2022
Q2 		$134K Buy
+2,969
New +$111K ﹤0.01% 11100
2021
Q4 		– Sell
-6,163
Closed -$1.3M – 14691
2021
Q3 		$1.3M Sell
6,163
-8,020
-57% -$1.46M ﹤0.01% 7466
2021
Q2 		$2.77M Sell
14,183
-20,444
-59% -$5.05M ﹤0.01% 5797
2021
Q1 		$10.1M Buy
+34,627
New +$11.6M ﹤0.01% 2954

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Citadel Advisors's FTH Position: Q2 2026 in Review

Citadel Advisors opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 12,296 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #11068 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in FTH as recently as Q4 2024.

Citadel Advisors first reported a position in FTH in Q1 2021 and has held it in 10 quarters since. The position peaked at $10.1M in Q1 2021. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Citadel Advisors held 12,296 shares of Faeth Therapeutics worth $307K as of Q2 2026.
  • Faeth Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Faeth Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11068 holding.
  • Citadel Advisors first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Citadel Advisors's Faeth Therapeutics position peaked at $10.1M in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.